medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2022, Número 2

<< Anterior Siguiente >>

Arch Neurocien 2022; 27 (2)


Therapeutic potential of dehydroepiandrosterone for Parkinson’s disease: scoping review protocol

Pérez-Neri I, Diéguez-Campa CE, Sandoval H, Chávez Vivian-Aleisha, Castro-Martínez E, Ríos C

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 39-46
Archivo PDF: 200.71 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Baltasar-Rodríguez LM, Millán-Guerrero RO, Aceves-ThemselR, Isais-Millán S, Delgado-Enciso I. Longitudinal study ofthree families with familial Parkinson’s disease. Gac Med Mex. 2006;142(5):387-91.

  2. Choe MA, An GJ, Koo BS, Jeon S. Effect of DHEA on recovery ofmuscle atrophy induced by Parkinson’s disease. J Korean AcadNurs. 2011;41(6):834-42.

  3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J.Epidemiology and etiology of Parkinson’s disease: a review ofthe evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1-58.

  4. Rizek P, Kumar N, Jog MS. An update on the diagnosis andtreatment of Parkinson disease. CMAJ. 2016;188(16):1157-65.

  5. Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T,Charalampopoulos I, et al. Neurosteroids as regulators ofneuroinflammation. Front Neuroendocrinol. 2019;55:100788.

  6. Carlström K, Brody S, Lunell NO, Lagrelius A, MöllerströmG, Pousette A, et al. Dehydroepiandrosterone sulphate anddehydroepiandrosterone in serum: differences related to ageand sex. Maturitas. 1988;10(4):297-306.

  7. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changesand sex differences in serum dehydroepiandrosterone sulfateconcentrations throughout adulthood. J Clin Endocrinol Metab.1984;59(3):551-5.

  8. Van Vollenhoven RF, McGuire JL. Studies of dehydroepiandrosterone(DHEA) as a therapeutic agent in systemic lupus erythematosus.Ann Med Interne (Paris). 1996;147(4):290-6.

  9. Pérez-Neri I, Ríos C. The role of DHEA in mental disorders. In:Watson R, editor. DHEA in Human Health and Aging. BocaRaton: CRC Press; 2011. p. 239-52.

  10. Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, StraubRH. Patients with refractory Crohn’s disease or ulcerative colitisrespond to dehydroepiandrosterone: a pilot study. AlimentPharmacol Ther. 2003;17(3):409-14.

  11. Fouany MR, Sharara FI. Is there a role for DHEA supplementationin women with diminished ovarian reserve. J Assist Reprod Genet.2013;30(9):1239-44.

  12. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens(dehydroepiandrosterone or testosterone) for womenundergoing assisted reproduction. Cochrane Database Syst Rev.2015;(11):CD009749.

  13. Evans TG, Judd ME, Dowell T, Poe S, Daynes RA, Araneo BA.The use of oral dehydroepiandrosterone sulfate as an adjuvantin tetanus and influenza vaccination of the elderly. Vaccine.1996;14(16):1531-37.

  14. Debonneuil EH, Quillard J, Baulieu EE. Hypoxia anddehydroepiandrosterone in old age: a mouse survival study.Respir Res. 2006;7:144.

  15. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectantagainst MPTP-induced neurotoxicity in C57/B1 mice.Neurotoxicol Teratol. 1996;18(5):603-6.

  16. Miller DB, Ali SF, O’Callaghan JP, Laws SC. The Impact of Genderand Estrogen on Striatal Dopaminergic Neurotoxicity. Ann N YAcad Sci. 1998;844(1):153-65.

  17. Murray HE, Pillai AV, McArthur SR, Razvi N, Datla KP, DexterDT, et al. Dose- and sex-dependent effects of the neurotoxin6-hydroxydopamine on the nigrostriatal dopaminergic pathwayof adult rats: differential actions of estrogen in males andfemales. Neuroscience. 2003;116(1):213-22.

  18. D’Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T.Dehydroepiandrosterone (DHEA) such as 17beta-estradiolprevents MPTP-induced dopamine depletion in mice. Synapse.2003;47(1):10-14.

  19. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, PetticrewM, et al. Preferred reporting items for systematic review andmeta-analysis protocols (PRISMA-P) 2015: elaboration andexplanation. BMJ. 2015;350:g7647.

  20. Esam H, Kanukula R, Dhurjati R, Aerram R, Chevireddy S,Bhaumik S, et al. Systematic reviews of antihypertensive drugs:A review of publication trends, characteristics, and quality. J ClinHypertens (Greenwich). 2021;23(5):915-22.

  21. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al. Cochrane handbook for systematic reviews of interventions.Chichester: John Wiley & Sons; 2019.

  22. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’s Disease inRomania: A Scoping Review Protocol. Brain Sci. 2021;11(2):251.

  23. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G,Buttery SC, Chynkiamis N, et al. Walking-related digital mobilityoutcomes as clinical trial endpoint measures: protocol for ascoping review. BMJ Open. 2020;10(7):e038704.

  24. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis.Adelaide: Joanna Briggs Institute; 2020.

  25. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, MulrowCD, et al. PRISMA 2020 explanation and elaboration: updatedguidance and exemplars for reporting systematic reviews. BMJ.2021;372:n160.

  26. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H,Chalmers I, et al. PRISMA for Abstracts: reporting systematicreviews in journal and conference abstracts. PLoS Med.2013;10(4):e1001419.

  27. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, etal. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklistand Explanation. Ann Intern Med. 2018;169(7):467-73.

  28. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V,Lefebvre C. PRESS Peer Review of Electronic Search Strategies:2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-6.

  29. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D,Page MJ, et al. PRISMA-S: an extension to the PRISMA Statementfor Reporting Literature Searches in Systematic Reviews. Syst Rev.2021;10(1):39.

  30. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. Theocular surface, coronaviruses and COVID -19. Clin Exp Optom.2020;103(4):418-24.

  31. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C,Ríos C. Therapeutic Potential of Ultrasound Neuromodulationin Decreasing Neuropathic Pain: Clinical and ExperimentalEvidence. Curr Neuropharmacol. 2021;19(3):334-48.

  32. McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicatingreferences. Syst Rev. 2021;10(1):38.

  33. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J, Luechtefeld T. Sysrev: A FAIR Platform for Data Curation and SystematicEvidence Review. Front Artif Intell. 2021;4:685298.

  34. Khamsi R. Coronavirus in context: Scite.ai tracks positive and negative citations for COVID-19 literature. Nature. 2020.

  35. Haddaway NR, McGuinness LA. PRISMA 2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (Version0.0.2). medRxiv. 2021:21260492.

  36. O’Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensuresconsideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol. 2014;67(1):56-64.

  37. Usher R, Stapleton T. Approaches for assessing decision-making capacity in older adults: a scoping review protocol. JBI Evidence Synthesis.2020;18(4):832-40.

  38. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studiesreporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147-53.

  39. Petticrew M, Roberts H. Systematic Reviews in the Social Sciences: A Practical Guide. Oxford: Wiley-Blackwell; 2006.

  40. Strech D, Synofzik M, Marckmann G. Systematic reviews of empirical bioethics. J Med Ethics. 2008;34(6):472-77.

  41. Tanila T, Tenhunen H, Hirvonen P. Value Mechanisms in the Implementation of Intelligent Patient Flow Management System - A MultipleCase Study. Stud Health Technol Inform. 2020;270:708-12.




2020     |     www.medigraphic.com